Keeping an eye on the ball in AML
Every once in a while a new approach comes along in acute leukemias, which turns everyone’s head.
CAR-T cell therapies certainly achieved this in pediatric ALL, as did the FLT3 and Bcl2 inhibitors in AML before them.
What are the next potential novel developments to think about?
Recently at ASH we explored progress with the Menin inhibitors, although they aren’t the only targeted therapy on the horizon.
In our latest in-depth analysis, we turn our attention to a very different kind of therapeutic intervention, which also happens to have a potential near-term binary event to consider.
This particular review includes an interview with company executives for their perspective on a late stage clinical program…
To continue reading our review on oncology new product development, including expert interviews plus commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
